Niowave-Novartis Deal Aims to Unlock Next-Gen Cancer Therapies

LANSING, MI – February 11, 2026 – A landmark agreement announced today between pharmaceutical giant Novartis and medical isotope producer Niowave Inc. aims to resolve a critical shortage of a rare radioactive material, potentially accelerating the development of a powerful new class of cancer treatments.

Under the long-term global supply agreement, Lansing-based Niowave will provide Novartis with Actinium-225 (Ac-225), a highly sought-after isotope essential for radioligand therapies (RLTs). These next-generation treatments are designed to act like guided missiles, delivering potent radiation directly to cancer cells while sparing surrounding healthy tissue. The deal secures a scalable supply for Novartis's growing portfolio of cancer drugs and will fuel a major expansion for Niowave, including the construction of a new manufacturing facility in Lansing slated to begin this year. Financial terms of the agreement were not disclosed.

The Promise of a 'Magic Bullet' Isotope

At the heart of this partnership is Actinium-225, an isotope widely regarded by oncologists as one of the most promising weapons in the fight against cancer. Its power lies in the type of radiation it emits: high-energy alpha particles. Unlike other forms of radiation, alpha particles travel a very short distance—less than the width of a human hair—and deposit a large amount of energy upon impact. When attached to a targeting molecule that seeks out specific proteins on the surface of cancer cells, Ac-225 can deliver a lethal, localized dose of radiation capable of causing double-stranded DNA breaks that cancer cells cannot repair.

This precision has earned RLTs the nickname "magic bullets." The approach is being investigated in clinical trials for a range of difficult-to-treat cancers, including prostate cancer, neuroendocrine tumors, leukemia, and melanoma. By destroying cancer cells with minimal collateral damage, these therapies hold the potential for greater efficacy with fewer of the debilitating side effects associated with traditional chemotherapy and radiation.

"Our new agreement with Novartis underscores Niowave's leading position as a trusted global supplier of medical radioisotopes," said Mike Zamiara, Chief Executive Officer of Niowave, in a statement. "Niowave's ability to provide dependable, scalable supply of Actinium-225 will contribute to the advancement of Novartis's targeted cancer therapies and has the potential to meaningfully transform cancer care on a global scale."

A Critical Bottleneck in Cancer Research

Despite its immense therapeutic promise, the widespread use of Ac-225 has been severely hampered by one fundamental problem: its extreme scarcity. The global supply of Ac-225 has historically been minuscule, enough to treat only a few thousand patients annually. This shortage has created a significant bottleneck, slowing down clinical research and limiting patient access to potentially life-saving treatments.

Historically, the world's supply of Ac-225 has been primarily derived from the decay of Thorium-229, a material itself sourced from stockpiles of Uranium-233 left over from Cold War-era nuclear programs. This finite and dwindling source has been unable to keep pace with the surging demand driven by the expanding field of radiopharmaceuticals. The market for Ac-225 is projected to grow at a compound annual rate of over 15%, highlighting the urgent need for new, scalable production methods.

The supply crunch has forced pharmaceutical companies to compete for the limited available material, with some clinical trials reportedly being delayed or halted due to a lack of isotope supply. This new agreement represents a crucial step in breaking that bottleneck.

Securing the Supply Chain for Future Cures

The Niowave-Novartis deal is a strategic move to de-risk Novartis's ambitious RLT pipeline. While the company recently discontinued an early-stage Ac-225 program for prostate cancer due to limited clinical benefit, it remains deeply committed to the platform. Its other actinium-based therapy, Ac-PSMA-617, is advancing into pivotal Phase 3 trials for metastatic castration-resistant prostate cancer, a testament to the company's confidence in the isotope's potential. Securing a reliable, long-term supply is therefore paramount to ensuring these advanced clinical programs can proceed and, if successful, reach commercial scale.

For Niowave, the agreement solidifies its role as a key player in the global radiopharmaceutical supply chain. Founded in 2005, the company has developed proprietary technology based on superconducting electron linear accelerators to produce Ac-225. This method, which involves irradiating a Radium-226 target to produce high-purity Ac-225, is designed for scalability in a way that historical methods are not. The company states its process creates an ultra-pure product, which is critical for patient safety and regulatory approval.

Michigan Emerges as a Global Hub for Isotope Production

To meet the demands of the Novartis partnership and the broader market, Niowave is embarking on a significant expansion. The company plans to begin construction of a new, dedicated radioisotope production facility in Lansing in early 2026. This move is poised to establish Michigan as a central hub in the high-tech world of medical isotope manufacturing, creating specialized jobs and bolstering the state's reputation for innovation in healthcare and advanced manufacturing.

Niowave is not alone in the race to scale up Ac-225 production. The intense demand has spurred a flurry of activity across the industry. Competitors like Wisconsin-based NorthStar Medical Radioisotopes recently announced its own commercial-scale production of Ac-225 using similar electron accelerator technology. Meanwhile, a transatlantic joint venture named Actineer, formed by Germany's ITM and Canadian Nuclear Laboratories, is also building out industrial-scale production capabilities. This competitive landscape underscores the immense value placed on Ac-225 and the strategic importance of building a resilient and robust supply chain to support the next wave of cancer therapies.